^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LYL845

    i
    Other names: LYL845, LYL-845, LYL 845
    Associations

    News

    Trials
    Company:
    Lyell Immunopharma
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    19d
    LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    12ms
    A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Lyell Immunopharma, Inc.
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    almost2years
    A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    2years
    A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Not yet recruiting, Lyell Immunopharma, Inc.
    New P1 trial • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845